Trial Profile
TECENTRIQ Drug Use Surveillance(advanced or recurrent non-small cell lung cancer)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jun 2022
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical
- 31 May 2022 Results assessing clinical tolerability and safety of atezolizumab in Japanese patients with non-small-cell lung cancer, published in the Japanese Journal of Clinical Oncology.
- 05 Jun 2020 Status changed from active, no longer recruiting to completed.
- 04 Apr 2019 Status changed from recruiting to active, no longer recruiting.